Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

Genomic aberrations are of predominant importance to the biology and clinical outcome of patients with chronic lymphocytic leukemia (CLL), and FISH-based genomic risk classifications are routinely used in clinical decision making in CLL. One of the known limitations of CLL FISH is the inability to comprehensively interrogate the CLL genome for genomic changes. In an effort at overcoming the existing limitations in CLL genome analysis, we have analyzed high-purity DNA isolated from FACS-sorted CD19(+) cells and paired CD3(+) or buccal cells from 255 patients with CLL for acquired genomic copy number aberrations (aCNAs) with the use of ultra-high-density Affymetrix SNP 6.0 arrays. Overall, ≥ 2 subchromosomal aCNAs were found in 39% (100 of 255) of all cases analyzed, whereas ≥ 3 subchromosomal aCNAs were detected in 20% (50 of 255) of cases. Subsequently, we have correlated genomic lesion loads (genomic complexity) with the clinical outcome measures time to first therapy and overall survival. With the use of multivariate analyses incorporating the most important prognostic factors in CLL together with SNP 6.0 array-based genomic lesion loads at various thresholds, we identify elevated CLL genomic complexity as an independent and powerful marker for the identification of patients with aggressive CLL and short survival.

[1]  Kerby Shedden,et al.  Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. , 2010, Blood.

[2]  M. Dyer,et al.  The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. , 2010, Blood.

[3]  C. Fegan,et al.  Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. , 2010, Blood.

[4]  George A Calin,et al.  microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. , 2010, Blood.

[5]  F. Nguyen‐Khac,et al.  Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. , 2010, Blood.

[6]  P. Ouillette,et al.  Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. , 2010, Blood.

[7]  Ronald Levy,et al.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.

[8]  L. Ding,et al.  Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks , 2010, Clinical Cancer Research.

[9]  J. Staaf,et al.  Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients , 2010, Leukemia.

[10]  ONSTANZE,et al.  GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .

[11]  Š. Pospíšilová,et al.  Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. , 2009, Blood.

[12]  Jeffrey A Jones,et al.  Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Kitzman,et al.  Acquired copy number alterations in adult acute myeloid leukemia genomes , 2009, Proceedings of the National Academy of Sciences.

[14]  Xavier Estivill,et al.  Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. , 2009, Blood.

[15]  B. Lakshmi,et al.  Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). , 2009, Blood.

[16]  D. Rossi,et al.  The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.

[17]  Susan O'Brien,et al.  De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. , 2008, Blood.

[18]  M J S Dyer,et al.  A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease , 2009, Leukemia.

[19]  T. Haferlach,et al.  The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype , 2009, Leukemia.

[20]  M. McDevitt,et al.  250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. , 2008, Cancer research.

[21]  N. Schmitz,et al.  Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Radich,et al.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Axel Benner,et al.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.

[24]  Sonia Jain,et al.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. , 2008, Blood.

[25]  T. Lister,et al.  Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. , 2008, Blood.

[26]  T. Shanafelt,et al.  Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Ogawa,et al.  Molecular allelokaryotyping of early‐stage, untreated chronic lymphocytic leukemia , 2008, Cancer.

[28]  M. Kaminski,et al.  Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. , 2007, Blood.

[29]  M. Kaminski,et al.  Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. , 2007, Blood.

[30]  J Wade Harper,et al.  The DNA damage response: ten years after. , 2007, Molecular cell.

[31]  R. Siebert,et al.  Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Haferlach,et al.  Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping , 2007, Leukemia.

[33]  A. Hagemeijer,et al.  Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine , 2007, Leukemia.

[34]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[35]  Jens Timmer,et al.  Using High-density Snp Arrays Genome-wide Analysis of Dna Copy Number Changes and Loh in Cll , 2022 .

[36]  Lisa L. Smith,et al.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. , 2006, Blood.

[37]  T. Haferlach,et al.  Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. , 2006, Blood.

[38]  C. Mayr,et al.  Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. , 2006, Blood.

[39]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[41]  J. Byrd,et al.  Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. , 2005, Blood.

[42]  Cheng Li,et al.  dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data , 2004, Bioinform..

[43]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[44]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[45]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[46]  C. Fegan,et al.  Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. , 1995, Leukemia.

[47]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[48]  B. Quesnel,et al.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.

[49]  E. Newcomb,et al.  p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression , 1993 .

[50]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.